CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V, Wells C, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Pal S, Meza L, Donskov F, Beuselinck B, Ernst M, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 318-318. DOI: 10.1200/jco.2022.40.6_suppl.318.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabTreatment failureOverall survivalInternational Metastatic Renal Cell Carcinoma Database Consortium criteriaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupAdvanced renal cell carcinomaResponse rateActivity of cabozantinibClinically meaningful activityRenal cell carcinomaEndothelial growth factorCell histologySarcomatoid componentBone metastasesVEGF inhibitorsPoor riskCell carcinomaCabozantinibHazard ratioRisk groupsPatientsGrowth factorTherapyEarly lines